Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
暂无分享,去创建一个
Mikael Lundin | Johan Lundin | Jorma Isola | Heikki Joensuu | Vesa Kataja | Tiina Salminen | V. Kataja | J. Isola | K. Holli | H. Joensuu | M. Lundin | J. Lundin | L. Pylkkänen | T. Turpeenniemi‐Hujanen | K. von Smitten | Kaija Holli | T. Salminen | Karl von Smitten | Taina Turpeenniemi-Hujanen | Liisa Pylkkänen
[1] Predicting response to endocrine therapy in human breast cancer: a hypothesis. , 1976, Science.
[2] S. Schnitt,et al. Prognostic factors for patients with breast cancers 1cm and smaller. , 1998 .
[3] I. Ellis,et al. Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.
[4] T. Dimpfl,et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.
[5] H. Joensuu,et al. Comparison of breast carcinomas diagnosed in the 1980s with those diagnosed in the 1940s to 1960s. , 1991, BMJ.
[6] R. W. Scarff,et al. Histological typing of breast tumors. , 1982, Tumori.
[7] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[8] S. Schnitt,et al. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma , 1998, Cancer.
[9] C. Benz,et al. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. R. Shetty. The new era in breast cancer. , 1996, Archives of surgery.
[11] L. Norton,et al. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Hutter,et al. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T 1 a,b NO MO) , 1995 .
[13] D. Hayes,et al. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. G. Schuler,et al. The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. , 1996, Archives of surgery.
[15] D. Larsimont,et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. , 2000, The American journal of pathology.
[16] H. Joensuu,et al. Late mortality from pT1N0M0 breast carcinoma , 1999, Cancer.
[17] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[18] D. Rimm,et al. Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.